Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Cerveau Announces Singapore Test of Neuro PET Imaging Agent

publication date: Dec 14, 2018

Cerveau Technologies, a partnership between Beijing Sinotau Pharma and Enigma Biomedical of Toronto, will start a Singapore trial of its PET imaging agent for neurofibrillary tangles (NFTs) in the brain, the first Asia test of the agent. Cerveau develops diagnostics and technology for neurodegenerative disorders including Alzheimer's disease. It in-licensed global rights to the agent, MK-6240, from Merck in early 2017 and has formed numerous collaborations around the globe to test its efficacy. Sinotau holds China rights to the imaging agent. More details....

Stock Symbol: (NYSE: MRK)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.